nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipyridamole—SLC29A1—Fluorouracil—skin cancer	0.215	0.401	CbGbCtD
Dipyridamole—ABCC5—Fluorouracil—skin cancer	0.164	0.307	CbGbCtD
Dipyridamole—ABCC4—Fluorouracil—skin cancer	0.0788	0.147	CbGbCtD
Dipyridamole—ABCB1—Vismodegib—skin cancer	0.043	0.0804	CbGbCtD
Dipyridamole—ABCB1—Dactinomycin—skin cancer	0.0226	0.0423	CbGbCtD
Dipyridamole—ABCB1—Docetaxel—skin cancer	0.0117	0.0218	CbGbCtD
Dipyridamole—PDE8B—leg—skin cancer	0.00837	0.0603	CbGeAlD
Dipyridamole—PDE8B—forelimb—skin cancer	0.00831	0.0598	CbGeAlD
Dipyridamole—PDE8B—hindlimb—skin cancer	0.00748	0.0538	CbGeAlD
Dipyridamole—PDE8B—appendage—skin cancer	0.00641	0.0462	CbGeAlD
Dipyridamole—PDE5A—penis—skin cancer	0.00607	0.0437	CbGeAlD
Dipyridamole—PDE3A—penis—skin cancer	0.00591	0.0425	CbGeAlD
Dipyridamole—PDE6A—mammalian vulva—skin cancer	0.00435	0.0313	CbGeAlD
Dipyridamole—PDE6B—connective tissue—skin cancer	0.00318	0.0229	CbGeAlD
Dipyridamole—PDE6A—head—skin cancer	0.00311	0.0224	CbGeAlD
Dipyridamole—PDE6C—head—skin cancer	0.00295	0.0212	CbGeAlD
Dipyridamole—PDE11A—epithelium—skin cancer	0.0028	0.0202	CbGeAlD
Dipyridamole—PDE2A—nipple—skin cancer	0.00271	0.0195	CbGeAlD
Dipyridamole—PDE8B—neck—skin cancer	0.00255	0.0184	CbGeAlD
Dipyridamole—PDE5A—endothelium—skin cancer	0.00238	0.0171	CbGeAlD
Dipyridamole—PDE8A—nipple—skin cancer	0.00232	0.0167	CbGeAlD
Dipyridamole—PDE6B—lymphoid tissue—skin cancer	0.00232	0.0167	CbGeAlD
Dipyridamole—PDE6D—female reproductive system—skin cancer	0.00228	0.0164	CbGeAlD
Dipyridamole—PDE5A—blood vessel—skin cancer	0.00219	0.0158	CbGeAlD
Dipyridamole—PDE1C—head—skin cancer	0.00218	0.0157	CbGeAlD
Dipyridamole—ABCC5—hair follicle—skin cancer	0.00214	0.0154	CbGeAlD
Dipyridamole—PDE7A—lymphoid tissue—skin cancer	0.00192	0.0138	CbGeAlD
Dipyridamole—PDE6B—head—skin cancer	0.00187	0.0135	CbGeAlD
Dipyridamole—PDE7A—female reproductive system—skin cancer	0.00186	0.0134	CbGeAlD
Dipyridamole—PDE3B—connective tissue—skin cancer	0.00179	0.0129	CbGeAlD
Dipyridamole—PDE6H—head—skin cancer	0.00174	0.0125	CbGeAlD
Dipyridamole—PDE6G—head—skin cancer	0.00167	0.012	CbGeAlD
Dipyridamole—PDE2A—mammalian vulva—skin cancer	0.00158	0.0114	CbGeAlD
Dipyridamole—PDE7A—head—skin cancer	0.00155	0.0112	CbGeAlD
Dipyridamole—PDE1C—lymph node—skin cancer	0.00153	0.011	CbGeAlD
Dipyridamole—PRUNE—lymph node—skin cancer	0.00138	0.00992	CbGeAlD
Dipyridamole—PDE8A—mammalian vulva—skin cancer	0.00136	0.00976	CbGeAlD
Dipyridamole—ADA—connective tissue—skin cancer	0.00136	0.00975	CbGeAlD
Dipyridamole—PDE7B—head—skin cancer	0.00135	0.00975	CbGeAlD
Dipyridamole—PDE2A—female reproductive system—skin cancer	0.00135	0.00974	CbGeAlD
Dipyridamole—PDE1B—female reproductive system—skin cancer	0.00134	0.00965	CbGeAlD
Dipyridamole—PDE6D—lymph node—skin cancer	0.00133	0.00958	CbGeAlD
Dipyridamole—SLC29A1—nipple—skin cancer	0.00133	0.00957	CbGeAlD
Dipyridamole—PDE8B—female reproductive system—skin cancer	0.00129	0.00929	CbGeAlD
Dipyridamole—PDE6G—lymph node—skin cancer	0.00117	0.00844	CbGeAlD
Dipyridamole—PDE10A—head—skin cancer	0.00113	0.00814	CbGeAlD
Dipyridamole—PDE2A—head—skin cancer	0.00113	0.00814	CbGeAlD
Dipyridamole—PDE1A—female reproductive system—skin cancer	0.00112	0.00809	CbGeAlD
Dipyridamole—PDE5A—connective tissue—skin cancer	0.00112	0.00808	CbGeAlD
Dipyridamole—PDE1B—head—skin cancer	0.00112	0.00807	CbGeAlD
Dipyridamole—ADA—mammalian vulva—skin cancer	0.00112	0.00803	CbGeAlD
Dipyridamole—PDE8B—head—skin cancer	0.00108	0.00776	CbGeAlD
Dipyridamole—PDE5A—epithelium—skin cancer	0.00107	0.00767	CbGeAlD
Dipyridamole—ADA—lymphoid tissue—skin cancer	0.000991	0.00713	CbGeAlD
Dipyridamole—ADA—female reproductive system—skin cancer	0.000956	0.00688	CbGeAlD
Dipyridamole—PDE7B—lymph node—skin cancer	0.000949	0.00683	CbGeAlD
Dipyridamole—SLC29A1—connective tissue—skin cancer	0.000943	0.00679	CbGeAlD
Dipyridamole—PDE1A—head—skin cancer	0.000939	0.00676	CbGeAlD
Dipyridamole—ADA—head—skin cancer	0.000799	0.00575	CbGeAlD
Dipyridamole—PDE5A—female reproductive system—skin cancer	0.000792	0.0057	CbGeAlD
Dipyridamole—PDE2A—lymph node—skin cancer	0.000792	0.0057	CbGeAlD
Dipyridamole—PDE10A—lymph node—skin cancer	0.000792	0.0057	CbGeAlD
Dipyridamole—PDE1B—lymph node—skin cancer	0.000785	0.00565	CbGeAlD
Dipyridamole—SLC29A1—mammalian vulva—skin cancer	0.000777	0.00559	CbGeAlD
Dipyridamole—PDE3A—female reproductive system—skin cancer	0.00077	0.00555	CbGeAlD
Dipyridamole—PDE8B—lymph node—skin cancer	0.000755	0.00544	CbGeAlD
Dipyridamole—PDE3B—lymph node—skin cancer	0.000738	0.00531	CbGeAlD
Dipyridamole—SLC29A1—lymphoid tissue—skin cancer	0.00069	0.00496	CbGeAlD
Dipyridamole—PDE8A—lymph node—skin cancer	0.000679	0.00489	CbGeAlD
Dipyridamole—SLC29A1—female reproductive system—skin cancer	0.000665	0.00479	CbGeAlD
Dipyridamole—PDE5A—head—skin cancer	0.000662	0.00476	CbGeAlD
Dipyridamole—PDE1A—lymph node—skin cancer	0.000658	0.00473	CbGeAlD
Dipyridamole—ADA—lymph node—skin cancer	0.000559	0.00402	CbGeAlD
Dipyridamole—SLC29A1—head—skin cancer	0.000556	0.004	CbGeAlD
Dipyridamole—PDE4A—lymph node—skin cancer	0.000545	0.00392	CbGeAlD
Dipyridamole—ABCC4—female reproductive system—skin cancer	0.000502	0.00361	CbGeAlD
Dipyridamole—ABCB1—blood vessel—skin cancer	0.000483	0.00348	CbGeAlD
Dipyridamole—PDE5A—lymph node—skin cancer	0.000463	0.00333	CbGeAlD
Dipyridamole—Flushing—Bleomycin—skin cancer	0.000454	0.00238	CcSEcCtD
Dipyridamole—Pharyngitis—Dactinomycin—skin cancer	0.000453	0.00237	CcSEcCtD
Dipyridamole—PDE3A—lymph node—skin cancer	0.000451	0.00324	CbGeAlD
Dipyridamole—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000446	0.00233	CcSEcCtD
Dipyridamole—Paraesthesia—Imiquimod—skin cancer	0.000439	0.0023	CcSEcCtD
Dipyridamole—Chills—Bleomycin—skin cancer	0.000439	0.0023	CcSEcCtD
Dipyridamole—Dyspnoea—Imiquimod—skin cancer	0.000436	0.00228	CcSEcCtD
Dipyridamole—Somnolence—Imiquimod—skin cancer	0.000435	0.00228	CcSEcCtD
Dipyridamole—Alopecia—Bleomycin—skin cancer	0.000432	0.00226	CcSEcCtD
Dipyridamole—Dyspepsia—Imiquimod—skin cancer	0.000431	0.00226	CcSEcCtD
Dipyridamole—Hot flush—Docetaxel—skin cancer	0.000424	0.00222	CcSEcCtD
Dipyridamole—ABCC5—lymph node—skin cancer	0.000424	0.00305	CbGeAlD
Dipyridamole—Flushing—Dactinomycin—skin cancer	0.000423	0.00222	CcSEcCtD
Dipyridamole—Hypersensitivity—Vemurafenib—skin cancer	0.000423	0.00221	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Imiquimod—skin cancer	0.000422	0.00221	CcSEcCtD
Dipyridamole—Fatigue—Imiquimod—skin cancer	0.000422	0.00221	CcSEcCtD
Dipyridamole—Menopausal symptoms—Docetaxel—skin cancer	0.00042	0.0022	CcSEcCtD
Dipyridamole—ABCC4—head—skin cancer	0.000419	0.00302	CbGeAlD
Dipyridamole—Atrial fibrillation—Docetaxel—skin cancer	0.000419	0.00219	CcSEcCtD
Dipyridamole—Pain—Imiquimod—skin cancer	0.000418	0.00219	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Fluorouracil—skin cancer	0.000417	0.00219	CcSEcCtD
Dipyridamole—Myocardial infarction—Fluorouracil—skin cancer	0.000415	0.00217	CcSEcCtD
Dipyridamole—Haemoglobin—Temozolomide—skin cancer	0.000415	0.00217	CcSEcCtD
Dipyridamole—Haemorrhage—Temozolomide—skin cancer	0.000413	0.00216	CcSEcCtD
Dipyridamole—Hepatitis—Temozolomide—skin cancer	0.000413	0.00216	CcSEcCtD
Dipyridamole—Asthenia—Vemurafenib—skin cancer	0.000412	0.00216	CcSEcCtD
Dipyridamole—Hypoaesthesia—Temozolomide—skin cancer	0.000411	0.00215	CcSEcCtD
Dipyridamole—Pharyngitis—Temozolomide—skin cancer	0.00041	0.00214	CcSEcCtD
Dipyridamole—Chills—Dactinomycin—skin cancer	0.000409	0.00214	CcSEcCtD
Dipyridamole—Pruritus—Vemurafenib—skin cancer	0.000406	0.00213	CcSEcCtD
Dipyridamole—Alopecia—Dactinomycin—skin cancer	0.000403	0.00211	CcSEcCtD
Dipyridamole—Feeling abnormal—Imiquimod—skin cancer	0.000403	0.00211	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Imiquimod—skin cancer	0.0004	0.00209	CcSEcCtD
Dipyridamole—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000397	0.00208	CcSEcCtD
Dipyridamole—Ill-defined disorder—Bleomycin—skin cancer	0.000395	0.00207	CcSEcCtD
Dipyridamole—Anaemia—Bleomycin—skin cancer	0.000394	0.00206	CcSEcCtD
Dipyridamole—Diarrhoea—Vemurafenib—skin cancer	0.000392	0.00206	CcSEcCtD
Dipyridamole—Migraine—Docetaxel—skin cancer	0.00039	0.00204	CcSEcCtD
Dipyridamole—SLC29A1—lymph node—skin cancer	0.000389	0.0028	CbGeAlD
Dipyridamole—Urticaria—Imiquimod—skin cancer	0.000389	0.00204	CcSEcCtD
Dipyridamole—Abdominal pain—Imiquimod—skin cancer	0.000387	0.00203	CcSEcCtD
Dipyridamole—Tinnitus—Temozolomide—skin cancer	0.000385	0.00201	CcSEcCtD
Dipyridamole—Malaise—Bleomycin—skin cancer	0.000384	0.00201	CcSEcCtD
Dipyridamole—Cardiac disorder—Temozolomide—skin cancer	0.000383	0.00201	CcSEcCtD
Dipyridamole—Flushing—Temozolomide—skin cancer	0.000383	0.00201	CcSEcCtD
Dipyridamole—Haemoglobin—Fluorouracil—skin cancer	0.000382	0.002	CcSEcCtD
Dipyridamole—Rhinitis—Fluorouracil—skin cancer	0.000381	0.002	CcSEcCtD
Dipyridamole—Haemorrhage—Fluorouracil—skin cancer	0.00038	0.00199	CcSEcCtD
Dipyridamole—Dizziness—Vemurafenib—skin cancer	0.000379	0.00199	CcSEcCtD
Dipyridamole—Hypoaesthesia—Fluorouracil—skin cancer	0.000378	0.00198	CcSEcCtD
Dipyridamole—Pharyngitis—Fluorouracil—skin cancer	0.000377	0.00198	CcSEcCtD
Dipyridamole—Angiopathy—Temozolomide—skin cancer	0.000374	0.00196	CcSEcCtD
Dipyridamole—Immune system disorder—Temozolomide—skin cancer	0.000373	0.00195	CcSEcCtD
Dipyridamole—Mediastinal disorder—Temozolomide—skin cancer	0.000372	0.00195	CcSEcCtD
Dipyridamole—Cough—Bleomycin—skin cancer	0.000372	0.00195	CcSEcCtD
Dipyridamole—Chills—Temozolomide—skin cancer	0.00037	0.00194	CcSEcCtD
Dipyridamole—Ill-defined disorder—Dactinomycin—skin cancer	0.000368	0.00193	CcSEcCtD
Dipyridamole—Anaemia—Dactinomycin—skin cancer	0.000367	0.00192	CcSEcCtD
Dipyridamole—Vomiting—Vemurafenib—skin cancer	0.000365	0.00191	CcSEcCtD
Dipyridamole—Alopecia—Temozolomide—skin cancer	0.000365	0.00191	CcSEcCtD
Dipyridamole—Myalgia—Bleomycin—skin cancer	0.000363	0.0019	CcSEcCtD
Dipyridamole—Chest pain—Bleomycin—skin cancer	0.000363	0.0019	CcSEcCtD
Dipyridamole—Abdominal pain upper—Docetaxel—skin cancer	0.000362	0.0019	CcSEcCtD
Dipyridamole—Orthostatic hypotension—Docetaxel—skin cancer	0.000362	0.0019	CcSEcCtD
Dipyridamole—Rash—Vemurafenib—skin cancer	0.000362	0.00189	CcSEcCtD
Dipyridamole—Dermatitis—Vemurafenib—skin cancer	0.000361	0.00189	CcSEcCtD
Dipyridamole—Hypersensitivity—Imiquimod—skin cancer	0.00036	0.00189	CcSEcCtD
Dipyridamole—Headache—Vemurafenib—skin cancer	0.000359	0.00188	CcSEcCtD
Dipyridamole—Discomfort—Bleomycin—skin cancer	0.000358	0.00188	CcSEcCtD
Dipyridamole—Malaise—Dactinomycin—skin cancer	0.000358	0.00188	CcSEcCtD
Dipyridamole—Cramp muscle—Docetaxel—skin cancer	0.000357	0.00187	CcSEcCtD
Dipyridamole—Dysgeusia—Temozolomide—skin cancer	0.000352	0.00184	CcSEcCtD
Dipyridamole—Asthenia—Imiquimod—skin cancer	0.000351	0.00184	CcSEcCtD
Dipyridamole—Oedema—Bleomycin—skin cancer	0.000348	0.00182	CcSEcCtD
Dipyridamole—Anaphylactic shock—Bleomycin—skin cancer	0.000348	0.00182	CcSEcCtD
Dipyridamole—Back pain—Temozolomide—skin cancer	0.000347	0.00182	CcSEcCtD
Dipyridamole—Pruritus—Imiquimod—skin cancer	0.000346	0.00181	CcSEcCtD
Dipyridamole—Dysphagia—Docetaxel—skin cancer	0.000343	0.0018	CcSEcCtD
Dipyridamole—Nausea—Vemurafenib—skin cancer	0.000341	0.00178	CcSEcCtD
Dipyridamole—Thrombocytopenia—Bleomycin—skin cancer	0.00034	0.00178	CcSEcCtD
Dipyridamole—Arrhythmia—Fluorouracil—skin cancer	0.00034	0.00178	CcSEcCtD
Dipyridamole—Myalgia—Dactinomycin—skin cancer	0.000338	0.00177	CcSEcCtD
Dipyridamole—Bronchospasm—Docetaxel—skin cancer	0.000337	0.00177	CcSEcCtD
Dipyridamole—Tremor—Temozolomide—skin cancer	0.000337	0.00176	CcSEcCtD
Dipyridamole—Alopecia—Fluorouracil—skin cancer	0.000336	0.00176	CcSEcCtD
Dipyridamole—Diarrhoea—Imiquimod—skin cancer	0.000335	0.00175	CcSEcCtD
Dipyridamole—Discomfort—Dactinomycin—skin cancer	0.000334	0.00175	CcSEcCtD
Dipyridamole—Angina pectoris—Docetaxel—skin cancer	0.000334	0.00175	CcSEcCtD
Dipyridamole—Ill-defined disorder—Temozolomide—skin cancer	0.000333	0.00175	CcSEcCtD
Dipyridamole—Anaemia—Temozolomide—skin cancer	0.000332	0.00174	CcSEcCtD
Dipyridamole—Angioedema—Temozolomide—skin cancer	0.000328	0.00172	CcSEcCtD
Dipyridamole—Hypotension—Bleomycin—skin cancer	0.000325	0.0017	CcSEcCtD
Dipyridamole—Oedema—Dactinomycin—skin cancer	0.000324	0.0017	CcSEcCtD
Dipyridamole—Malaise—Temozolomide—skin cancer	0.000324	0.0017	CcSEcCtD
Dipyridamole—Dizziness—Imiquimod—skin cancer	0.000323	0.00169	CcSEcCtD
Dipyridamole—Vertigo—Temozolomide—skin cancer	0.000323	0.00169	CcSEcCtD
Dipyridamole—Palpitations—Temozolomide—skin cancer	0.000317	0.00166	CcSEcCtD
Dipyridamole—Thrombocytopenia—Dactinomycin—skin cancer	0.000317	0.00166	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000317	0.00166	CcSEcCtD
Dipyridamole—Cough—Temozolomide—skin cancer	0.000313	0.00164	CcSEcCtD
Dipyridamole—Paraesthesia—Bleomycin—skin cancer	0.000312	0.00163	CcSEcCtD
Dipyridamole—Convulsion—Temozolomide—skin cancer	0.000311	0.00163	CcSEcCtD
Dipyridamole—Vomiting—Imiquimod—skin cancer	0.000311	0.00163	CcSEcCtD
Dipyridamole—Hypertension—Temozolomide—skin cancer	0.00031	0.00162	CcSEcCtD
Dipyridamole—Dyspnoea—Bleomycin—skin cancer	0.00031	0.00162	CcSEcCtD
Dipyridamole—Rash—Imiquimod—skin cancer	0.000308	0.00162	CcSEcCtD
Dipyridamole—Dermatitis—Imiquimod—skin cancer	0.000308	0.00161	CcSEcCtD
Dipyridamole—Headache—Imiquimod—skin cancer	0.000306	0.0016	CcSEcCtD
Dipyridamole—Anaemia—Fluorouracil—skin cancer	0.000306	0.0016	CcSEcCtD
Dipyridamole—Arthralgia—Temozolomide—skin cancer	0.000306	0.0016	CcSEcCtD
Dipyridamole—Myalgia—Temozolomide—skin cancer	0.000306	0.0016	CcSEcCtD
Dipyridamole—Anxiety—Temozolomide—skin cancer	0.000305	0.0016	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000304	0.00159	CcSEcCtD
Dipyridamole—Discomfort—Temozolomide—skin cancer	0.000302	0.00158	CcSEcCtD
Dipyridamole—Acute coronary syndrome—Docetaxel—skin cancer	0.000301	0.00158	CcSEcCtD
Dipyridamole—Myocardial infarction—Docetaxel—skin cancer	0.0003	0.00157	CcSEcCtD
Dipyridamole—Dry mouth—Temozolomide—skin cancer	0.000299	0.00157	CcSEcCtD
Dipyridamole—Pain—Bleomycin—skin cancer	0.000297	0.00156	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000295	0.00155	CcSEcCtD
Dipyridamole—ABCC4—lymph node—skin cancer	0.000294	0.00211	CbGeAlD
Dipyridamole—Anaphylactic shock—Temozolomide—skin cancer	0.000293	0.00154	CcSEcCtD
Dipyridamole—Oedema—Temozolomide—skin cancer	0.000293	0.00154	CcSEcCtD
Dipyridamole—Nausea—Imiquimod—skin cancer	0.000291	0.00152	CcSEcCtD
Dipyridamole—Nervous system disorder—Temozolomide—skin cancer	0.000287	0.00151	CcSEcCtD
Dipyridamole—Thrombocytopenia—Temozolomide—skin cancer	0.000287	0.0015	CcSEcCtD
Dipyridamole—Convulsion—Fluorouracil—skin cancer	0.000287	0.0015	CcSEcCtD
Dipyridamole—Feeling abnormal—Bleomycin—skin cancer	0.000286	0.0015	CcSEcCtD
Dipyridamole—Skin disorder—Temozolomide—skin cancer	0.000285	0.00149	CcSEcCtD
Dipyridamole—Hyperhidrosis—Temozolomide—skin cancer	0.000283	0.00148	CcSEcCtD
Dipyridamole—Chest pain—Fluorouracil—skin cancer	0.000282	0.00148	CcSEcCtD
Dipyridamole—Myalgia—Fluorouracil—skin cancer	0.000282	0.00148	CcSEcCtD
Dipyridamole—Fatigue—Dactinomycin—skin cancer	0.000279	0.00146	CcSEcCtD
Dipyridamole—Discomfort—Fluorouracil—skin cancer	0.000278	0.00146	CcSEcCtD
Dipyridamole—Pain—Dactinomycin—skin cancer	0.000277	0.00145	CcSEcCtD
Dipyridamole—Urticaria—Bleomycin—skin cancer	0.000276	0.00145	CcSEcCtD
Dipyridamole—Haemoglobin—Docetaxel—skin cancer	0.000276	0.00144	CcSEcCtD
Dipyridamole—Rhinitis—Docetaxel—skin cancer	0.000275	0.00144	CcSEcCtD
Dipyridamole—Hepatitis—Docetaxel—skin cancer	0.000274	0.00144	CcSEcCtD
Dipyridamole—Haemorrhage—Docetaxel—skin cancer	0.000274	0.00144	CcSEcCtD
Dipyridamole—Hypoaesthesia—Docetaxel—skin cancer	0.000273	0.00143	CcSEcCtD
Dipyridamole—Pharyngitis—Docetaxel—skin cancer	0.000272	0.00143	CcSEcCtD
Dipyridamole—Anaphylactic shock—Fluorouracil—skin cancer	0.00027	0.00141	CcSEcCtD
Dipyridamole—Oedema—Fluorouracil—skin cancer	0.00027	0.00141	CcSEcCtD
Dipyridamole—Feeling abnormal—Dactinomycin—skin cancer	0.000267	0.0014	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000267	0.0014	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Dactinomycin—skin cancer	0.000265	0.00139	CcSEcCtD
Dipyridamole—Nervous system disorder—Fluorouracil—skin cancer	0.000265	0.00139	CcSEcCtD
Dipyridamole—Thrombocytopenia—Fluorouracil—skin cancer	0.000264	0.00139	CcSEcCtD
Dipyridamole—Tachycardia—Fluorouracil—skin cancer	0.000264	0.00138	CcSEcCtD
Dipyridamole—Paraesthesia—Temozolomide—skin cancer	0.000263	0.00138	CcSEcCtD
Dipyridamole—Dyspnoea—Temozolomide—skin cancer	0.000261	0.00137	CcSEcCtD
Dipyridamole—Somnolence—Temozolomide—skin cancer	0.000261	0.00136	CcSEcCtD
Dipyridamole—Dyspepsia—Temozolomide—skin cancer	0.000258	0.00135	CcSEcCtD
Dipyridamole—Abdominal pain—Dactinomycin—skin cancer	0.000256	0.00134	CcSEcCtD
Dipyridamole—Hypersensitivity—Bleomycin—skin cancer	0.000256	0.00134	CcSEcCtD
Dipyridamole—Flushing—Docetaxel—skin cancer	0.000255	0.00133	CcSEcCtD
Dipyridamole—Cardiac disorder—Docetaxel—skin cancer	0.000255	0.00133	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Temozolomide—skin cancer	0.000253	0.00133	CcSEcCtD
Dipyridamole—Fatigue—Temozolomide—skin cancer	0.000253	0.00132	CcSEcCtD
Dipyridamole—Hypotension—Fluorouracil—skin cancer	0.000252	0.00132	CcSEcCtD
Dipyridamole—Pain—Temozolomide—skin cancer	0.000251	0.00131	CcSEcCtD
Dipyridamole—Asthenia—Bleomycin—skin cancer	0.000249	0.00131	CcSEcCtD
Dipyridamole—Angiopathy—Docetaxel—skin cancer	0.000249	0.0013	CcSEcCtD
Dipyridamole—Immune system disorder—Docetaxel—skin cancer	0.000248	0.0013	CcSEcCtD
Dipyridamole—Mediastinal disorder—Docetaxel—skin cancer	0.000247	0.0013	CcSEcCtD
Dipyridamole—Chills—Docetaxel—skin cancer	0.000246	0.00129	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000246	0.00129	CcSEcCtD
Dipyridamole—Pruritus—Bleomycin—skin cancer	0.000246	0.00129	CcSEcCtD
Dipyridamole—Arrhythmia—Docetaxel—skin cancer	0.000245	0.00128	CcSEcCtD
Dipyridamole—Paraesthesia—Fluorouracil—skin cancer	0.000243	0.00127	CcSEcCtD
Dipyridamole—Alopecia—Docetaxel—skin cancer	0.000242	0.00127	CcSEcCtD
Dipyridamole—Feeling abnormal—Temozolomide—skin cancer	0.000242	0.00127	CcSEcCtD
Dipyridamole—Dyspnoea—Fluorouracil—skin cancer	0.000241	0.00126	CcSEcCtD
Dipyridamole—Somnolence—Fluorouracil—skin cancer	0.00024	0.00126	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Temozolomide—skin cancer	0.00024	0.00126	CcSEcCtD
Dipyridamole—Hypersensitivity—Dactinomycin—skin cancer	0.000239	0.00125	CcSEcCtD
Dipyridamole—Dyspepsia—Fluorouracil—skin cancer	0.000238	0.00125	CcSEcCtD
Dipyridamole—ABCB1—epithelium—skin cancer	0.000235	0.00169	CbGeAlD
Dipyridamole—Dysgeusia—Docetaxel—skin cancer	0.000234	0.00123	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000233	0.00122	CcSEcCtD
Dipyridamole—Urticaria—Temozolomide—skin cancer	0.000233	0.00122	CcSEcCtD
Dipyridamole—Asthenia—Dactinomycin—skin cancer	0.000233	0.00122	CcSEcCtD
Dipyridamole—Abdominal pain—Temozolomide—skin cancer	0.000232	0.00121	CcSEcCtD
Dipyridamole—Back pain—Docetaxel—skin cancer	0.000231	0.00121	CcSEcCtD
Dipyridamole—Pain—Fluorouracil—skin cancer	0.000231	0.00121	CcSEcCtD
Dipyridamole—Muscle spasms—Docetaxel—skin cancer	0.00023	0.0012	CcSEcCtD
Dipyridamole—Feeling abnormal—Fluorouracil—skin cancer	0.000223	0.00117	CcSEcCtD
Dipyridamole—Diarrhoea—Dactinomycin—skin cancer	0.000222	0.00116	CcSEcCtD
Dipyridamole—Vomiting—Bleomycin—skin cancer	0.000221	0.00116	CcSEcCtD
Dipyridamole—Anaemia—Docetaxel—skin cancer	0.000221	0.00116	CcSEcCtD
Dipyridamole—Rash—Bleomycin—skin cancer	0.000219	0.00115	CcSEcCtD
Dipyridamole—Dermatitis—Bleomycin—skin cancer	0.000219	0.00115	CcSEcCtD
Dipyridamole—Hypersensitivity—Temozolomide—skin cancer	0.000216	0.00113	CcSEcCtD
Dipyridamole—Urticaria—Fluorouracil—skin cancer	0.000215	0.00112	CcSEcCtD
Dipyridamole—Syncope—Docetaxel—skin cancer	0.000214	0.00112	CcSEcCtD
Dipyridamole—Palpitations—Docetaxel—skin cancer	0.000211	0.00111	CcSEcCtD
Dipyridamole—Asthenia—Temozolomide—skin cancer	0.00021	0.0011	CcSEcCtD
Dipyridamole—Loss of consciousness—Docetaxel—skin cancer	0.00021	0.0011	CcSEcCtD
Dipyridamole—Cough—Docetaxel—skin cancer	0.000208	0.00109	CcSEcCtD
Dipyridamole—Pruritus—Temozolomide—skin cancer	0.000207	0.00109	CcSEcCtD
Dipyridamole—Convulsion—Docetaxel—skin cancer	0.000207	0.00108	CcSEcCtD
Dipyridamole—Nausea—Bleomycin—skin cancer	0.000206	0.00108	CcSEcCtD
Dipyridamole—Hypertension—Docetaxel—skin cancer	0.000206	0.00108	CcSEcCtD
Dipyridamole—Vomiting—Dactinomycin—skin cancer	0.000206	0.00108	CcSEcCtD
Dipyridamole—Rash—Dactinomycin—skin cancer	0.000204	0.00107	CcSEcCtD
Dipyridamole—ABCB1—mammalian vulva—skin cancer	0.000204	0.00147	CbGeAlD
Dipyridamole—Myalgia—Docetaxel—skin cancer	0.000203	0.00107	CcSEcCtD
Dipyridamole—Arthralgia—Docetaxel—skin cancer	0.000203	0.00107	CcSEcCtD
Dipyridamole—Chest pain—Docetaxel—skin cancer	0.000203	0.00107	CcSEcCtD
Dipyridamole—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000202	0.00106	CcSEcCtD
Dipyridamole—Diarrhoea—Temozolomide—skin cancer	0.000201	0.00105	CcSEcCtD
Dipyridamole—Hypersensitivity—Fluorouracil—skin cancer	0.000199	0.00104	CcSEcCtD
Dipyridamole—Dry mouth—Docetaxel—skin cancer	0.000199	0.00104	CcSEcCtD
Dipyridamole—Oedema—Docetaxel—skin cancer	0.000195	0.00102	CcSEcCtD
Dipyridamole—Anaphylactic shock—Docetaxel—skin cancer	0.000195	0.00102	CcSEcCtD
Dipyridamole—Dizziness—Temozolomide—skin cancer	0.000194	0.00102	CcSEcCtD
Dipyridamole—Nausea—Dactinomycin—skin cancer	0.000193	0.00101	CcSEcCtD
Dipyridamole—Shock—Docetaxel—skin cancer	0.000192	0.001	CcSEcCtD
Dipyridamole—Nervous system disorder—Docetaxel—skin cancer	0.000191	0.001	CcSEcCtD
Dipyridamole—Pruritus—Fluorouracil—skin cancer	0.000191	0.001	CcSEcCtD
Dipyridamole—Thrombocytopenia—Docetaxel—skin cancer	0.000191	0.001	CcSEcCtD
Dipyridamole—Tachycardia—Docetaxel—skin cancer	0.00019	0.000996	CcSEcCtD
Dipyridamole—Skin disorder—Docetaxel—skin cancer	0.000189	0.000992	CcSEcCtD
Dipyridamole—Vomiting—Temozolomide—skin cancer	0.000186	0.000976	CcSEcCtD
Dipyridamole—Rash—Temozolomide—skin cancer	0.000185	0.000968	CcSEcCtD
Dipyridamole—Diarrhoea—Fluorouracil—skin cancer	0.000185	0.000968	CcSEcCtD
Dipyridamole—Dermatitis—Temozolomide—skin cancer	0.000185	0.000967	CcSEcCtD
Dipyridamole—Headache—Temozolomide—skin cancer	0.000184	0.000962	CcSEcCtD
Dipyridamole—Hypotension—Docetaxel—skin cancer	0.000182	0.000954	CcSEcCtD
Dipyridamole—ABCB1—lymphoid tissue—skin cancer	0.000181	0.0013	CbGeAlD
Dipyridamole—Dizziness—Fluorouracil—skin cancer	0.000179	0.000935	CcSEcCtD
Dipyridamole—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000178	0.00093	CcSEcCtD
Dipyridamole—Paraesthesia—Docetaxel—skin cancer	0.000175	0.000917	CcSEcCtD
Dipyridamole—ABCB1—female reproductive system—skin cancer	0.000175	0.00126	CbGeAlD
Dipyridamole—Nausea—Temozolomide—skin cancer	0.000174	0.000912	CcSEcCtD
Dipyridamole—Dyspnoea—Docetaxel—skin cancer	0.000174	0.00091	CcSEcCtD
Dipyridamole—Somnolence—Docetaxel—skin cancer	0.000173	0.000908	CcSEcCtD
Dipyridamole—Vomiting—Fluorouracil—skin cancer	0.000172	0.000899	CcSEcCtD
Dipyridamole—Dyspepsia—Docetaxel—skin cancer	0.000172	0.000899	CcSEcCtD
Dipyridamole—Rash—Fluorouracil—skin cancer	0.00017	0.000892	CcSEcCtD
Dipyridamole—Dermatitis—Fluorouracil—skin cancer	0.00017	0.000891	CcSEcCtD
Dipyridamole—Headache—Fluorouracil—skin cancer	0.000169	0.000886	CcSEcCtD
Dipyridamole—Gastrointestinal disorder—Docetaxel—skin cancer	0.000168	0.000881	CcSEcCtD
Dipyridamole—Fatigue—Docetaxel—skin cancer	0.000168	0.00088	CcSEcCtD
Dipyridamole—Pain—Docetaxel—skin cancer	0.000167	0.000873	CcSEcCtD
Dipyridamole—Feeling abnormal—Docetaxel—skin cancer	0.000161	0.000841	CcSEcCtD
Dipyridamole—Nausea—Fluorouracil—skin cancer	0.00016	0.00084	CcSEcCtD
Dipyridamole—Gastrointestinal pain—Docetaxel—skin cancer	0.000159	0.000835	CcSEcCtD
Dipyridamole—Abdominal pain—Docetaxel—skin cancer	0.000154	0.000807	CcSEcCtD
Dipyridamole—ABCB1—head—skin cancer	0.000146	0.00105	CbGeAlD
Dipyridamole—Hypersensitivity—Docetaxel—skin cancer	0.000144	0.000752	CcSEcCtD
Dipyridamole—Asthenia—Docetaxel—skin cancer	0.00014	0.000733	CcSEcCtD
Dipyridamole—Pruritus—Docetaxel—skin cancer	0.000138	0.000722	CcSEcCtD
Dipyridamole—Diarrhoea—Docetaxel—skin cancer	0.000133	0.000699	CcSEcCtD
Dipyridamole—Dizziness—Docetaxel—skin cancer	0.000129	0.000675	CcSEcCtD
Dipyridamole—Vomiting—Docetaxel—skin cancer	0.000124	0.000649	CcSEcCtD
Dipyridamole—Rash—Docetaxel—skin cancer	0.000123	0.000644	CcSEcCtD
Dipyridamole—Dermatitis—Docetaxel—skin cancer	0.000123	0.000643	CcSEcCtD
Dipyridamole—Headache—Docetaxel—skin cancer	0.000122	0.00064	CcSEcCtD
Dipyridamole—Nausea—Docetaxel—skin cancer	0.000116	0.000606	CcSEcCtD
Dipyridamole—ABCB1—lymph node—skin cancer	0.000102	0.000736	CbGeAlD
Dipyridamole—PDE3B—Signaling Pathways—FOXO4—skin cancer	4.36e-05	0.000322	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—SMO—skin cancer	4.34e-05	0.00032	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTCH1—skin cancer	4.34e-05	0.00032	CbGpPWpGaD
Dipyridamole—PDE1C—Innate Immune System—IL6—skin cancer	4.33e-05	0.00032	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—KRAS—skin cancer	4.3e-05	0.000318	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—BRAF—skin cancer	4.3e-05	0.000317	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—PTGS2—skin cancer	4.27e-05	0.000316	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—NRAS—skin cancer	4.27e-05	0.000316	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—NRAS—skin cancer	4.25e-05	0.000314	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—NRAS—skin cancer	4.25e-05	0.000314	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by NGF—HRAS—skin cancer	4.22e-05	0.000312	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—PTGER4—skin cancer	4.22e-05	0.000312	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—PTGS2—skin cancer	4.21e-05	0.000311	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SHH—skin cancer	4.18e-05	0.000309	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—RASA1—skin cancer	4.16e-05	0.000307	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—FOXO4—skin cancer	4.08e-05	0.000301	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by NGF—IL6—skin cancer	4.04e-05	0.000299	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—BRAF—skin cancer	3.99e-05	0.000295	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—BRAF—skin cancer	3.99e-05	0.000295	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTCH1—skin cancer	3.97e-05	0.000293	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—FOXO4—skin cancer	3.97e-05	0.000293	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—SMO—skin cancer	3.97e-05	0.000293	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.94e-05	0.000291	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—NRAS—skin cancer	3.94e-05	0.000291	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—KRAS—skin cancer	3.93e-05	0.000291	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—NRAS—skin cancer	3.89e-05	0.000287	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by NGF—HRAS—skin cancer	3.86e-05	0.000285	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—PTGER4—skin cancer	3.86e-05	0.000285	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—ERCC2—skin cancer	3.8e-05	0.00028	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—ERCC2—skin cancer	3.8e-05	0.00028	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—NRAS—skin cancer	3.79e-05	0.00028	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling by GPCR—HRAS—skin cancer	3.75e-05	0.000277	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling by GPCR—HRAS—skin cancer	3.75e-05	0.000277	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—FOXO4—skin cancer	3.73e-05	0.000276	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—HRAS—skin cancer	3.72e-05	0.000275	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—HRAS—skin cancer	3.72e-05	0.000275	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—BRAF—skin cancer	3.7e-05	0.000274	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by NGF—IL6—skin cancer	3.7e-05	0.000273	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—KRAS—skin cancer	3.68e-05	0.000272	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—KRAS—skin cancer	3.66e-05	0.00027	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—KRAS—skin cancer	3.66e-05	0.00027	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—NRAS—skin cancer	3.66e-05	0.00027	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—HRAS—skin cancer	3.66e-05	0.00027	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—BRAF—skin cancer	3.65e-05	0.00027	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—NRAS—skin cancer	3.6e-05	0.000266	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling by GPCR—IL6—skin cancer	3.59e-05	0.000265	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling by GPCR—IL6—skin cancer	3.59e-05	0.000265	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—NRAS—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—NRAS—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE6A—Disease—IL6—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE6B—Disease—IL6—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—BRAF—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—TERT—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—TERT—skin cancer	3.56e-05	0.000263	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling by GPCR—IL6—skin cancer	3.5e-05	0.000259	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—ERCC2—skin cancer	3.47e-05	0.000256	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—FOXO4—skin cancer	3.41e-05	0.000252	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—KRAS—skin cancer	3.39e-05	0.000251	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—KRAS—skin cancer	3.35e-05	0.000247	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—NRAS—skin cancer	3.34e-05	0.000247	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—HRAS—skin cancer	3.34e-05	0.000247	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—NRAS—skin cancer	3.32e-05	0.000246	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—NRAS—skin cancer	3.29e-05	0.000243	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—NRAS—skin cancer	3.28e-05	0.000242	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—TP53—skin cancer	3.27e-05	0.000241	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—KRAS—skin cancer	3.26e-05	0.000241	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—TERT—skin cancer	3.25e-05	0.00024	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling by GPCR—IL6—skin cancer	3.2e-05	0.000236	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—ERCC2—skin cancer	3.18e-05	0.000235	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—KRAS—skin cancer	3.15e-05	0.000233	CbGpPWpGaD
Dipyridamole—PDE3B—Hemostasis—HRAS—skin cancer	3.12e-05	0.000231	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—HRAS—skin cancer	3.11e-05	0.00023	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—HRAS—skin cancer	3.11e-05	0.00023	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—KRAS—skin cancer	3.1e-05	0.000229	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—KRAS—skin cancer	3.07e-05	0.000227	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—KRAS—skin cancer	3.07e-05	0.000227	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—NRAS—skin cancer	3.03e-05	0.000224	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—NRAS—skin cancer	3.03e-05	0.000224	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—NRAS—skin cancer	3.01e-05	0.000223	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling by GPCR—IL6—skin cancer	2.98e-05	0.00022	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling by GPCR—IL6—skin cancer	2.98e-05	0.00022	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—TP53—skin cancer	2.98e-05	0.00022	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—NRAS—skin cancer	2.95e-05	0.000218	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TERT—skin cancer	2.91e-05	0.000215	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—HRAS—skin cancer	2.88e-05	0.000213	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—KRAS—skin cancer	2.88e-05	0.000213	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—KRAS—skin cancer	2.86e-05	0.000211	CbGpPWpGaD
Dipyridamole—PDE3A—Hemostasis—HRAS—skin cancer	2.85e-05	0.00021	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—KRAS—skin cancer	2.83e-05	0.000209	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—KRAS—skin cancer	2.82e-05	0.000209	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—BRAF—skin cancer	2.82e-05	0.000208	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—BRAF—skin cancer	2.82e-05	0.000208	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.82e-05	0.000208	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—TP53—skin cancer	2.8e-05	0.000207	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—HRAS—skin cancer	2.77e-05	0.000205	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling by GPCR—IL6—skin cancer	2.76e-05	0.000204	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PLIN2—skin cancer	2.74e-05	0.000203	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—TP53—skin cancer	2.73e-05	0.000201	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—TP53—skin cancer	2.73e-05	0.000201	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TERT—skin cancer	2.72e-05	0.000201	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—NRAS—skin cancer	2.7e-05	0.0002	CbGpPWpGaD
Dipyridamole—PDE1A—Hemostasis—HRAS—skin cancer	2.68e-05	0.000198	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling by GPCR—IL6—skin cancer	2.65e-05	0.000196	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TERT—skin cancer	2.65e-05	0.000196	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—HRAS—skin cancer	2.63e-05	0.000195	CbGpPWpGaD
Dipyridamole—ADA—Metabolism—PTGS2—skin cancer	2.62e-05	0.000194	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—KRAS—skin cancer	2.61e-05	0.000193	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—KRAS—skin cancer	2.61e-05	0.000193	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—HRAS—skin cancer	2.61e-05	0.000193	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—HRAS—skin cancer	2.61e-05	0.000193	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—KRAS—skin cancer	2.59e-05	0.000192	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—BRAF—skin cancer	2.58e-05	0.00019	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—TP53—skin cancer	2.56e-05	0.000189	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—KRAS—skin cancer	2.54e-05	0.000188	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—NRAS—skin cancer	2.53e-05	0.000187	CbGpPWpGaD
Dipyridamole—PDE1C—Immune System—IL6—skin cancer	2.52e-05	0.000186	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—NRAS—skin cancer	2.51e-05	0.000185	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—NRAS—skin cancer	2.51e-05	0.000185	CbGpPWpGaD
Dipyridamole—PDE6A—Signaling Pathways—IL6—skin cancer	2.49e-05	0.000184	CbGpPWpGaD
Dipyridamole—PDE6B—Signaling Pathways—IL6—skin cancer	2.49e-05	0.000184	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TERT—skin cancer	2.49e-05	0.000184	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—NRAS—skin cancer	2.45e-05	0.000181	CbGpPWpGaD
Dipyridamole—PDE1B—Hemostasis—HRAS—skin cancer	2.45e-05	0.000181	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—HRAS—skin cancer	2.43e-05	0.00018	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—HRAS—skin cancer	2.41e-05	0.000178	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—HRAS—skin cancer	2.4e-05	0.000177	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—NRAS—skin cancer	2.33e-05	0.000172	CbGpPWpGaD
Dipyridamole—PDE1C—Disease—IL6—skin cancer	2.33e-05	0.000172	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—KRAS—skin cancer	2.32e-05	0.000172	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—TP53—skin cancer	2.32e-05	0.000171	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—TP53—skin cancer	2.32e-05	0.000171	CbGpPWpGaD
Dipyridamole—PDE1A—Innate Immune System—IL6—skin cancer	2.31e-05	0.00017	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—BRAF—skin cancer	2.3e-05	0.00017	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—NRAS—skin cancer	2.3e-05	0.00017	CbGpPWpGaD
Dipyridamole—PDE6G—Disease—IL6—skin cancer	2.3e-05	0.00017	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—NRAS—skin cancer	2.29e-05	0.00017	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TERT—skin cancer	2.28e-05	0.000168	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—PTGS2—skin cancer	2.28e-05	0.000168	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—PTGS2—skin cancer	2.28e-05	0.000168	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—TP53—skin cancer	2.26e-05	0.000167	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—NRAS—skin cancer	2.24e-05	0.000165	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—NRAS—skin cancer	2.23e-05	0.000165	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—HRAS—skin cancer	2.22e-05	0.000164	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—HRAS—skin cancer	2.22e-05	0.000164	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—CSPG4—skin cancer	2.21e-05	0.000163	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—HRAS—skin cancer	2.2e-05	0.000163	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—KRAS—skin cancer	2.18e-05	0.000161	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—KRAS—skin cancer	2.16e-05	0.00016	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—KRAS—skin cancer	2.16e-05	0.00016	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—HRAS—skin cancer	2.16e-05	0.00016	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—BRAF—skin cancer	2.16e-05	0.000159	CbGpPWpGaD
Dipyridamole—PDE8A—Signaling Pathways—IL6—skin cancer	2.12e-05	0.000157	CbGpPWpGaD
Dipyridamole—PDE8B—Signaling Pathways—IL6—skin cancer	2.12e-05	0.000157	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—KRAS—skin cancer	2.11e-05	0.000156	CbGpPWpGaD
Dipyridamole—PDE1B—Innate Immune System—IL6—skin cancer	2.11e-05	0.000156	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—NRAS—skin cancer	2.1e-05	0.000155	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—BRAF—skin cancer	2.1e-05	0.000155	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—PTGS2—skin cancer	2.08e-05	0.000154	CbGpPWpGaD
Dipyridamole—PDE2A—Signaling Pathways—IL6—skin cancer	2.07e-05	0.000153	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—TP53—skin cancer	2.07e-05	0.000153	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—KRAS—skin cancer	2e-05	0.000148	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—KRAS—skin cancer	1.98e-05	0.000146	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—HRAS—skin cancer	1.98e-05	0.000146	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—KRAS—skin cancer	1.98e-05	0.000146	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—BRAF—skin cancer	1.97e-05	0.000146	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—TP53—skin cancer	1.94e-05	0.000143	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—KRAS—skin cancer	1.93e-05	0.000142	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—KRAS—skin cancer	1.92e-05	0.000142	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—TP53—skin cancer	1.92e-05	0.000142	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—TP53—skin cancer	1.92e-05	0.000142	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—NRAS—skin cancer	1.92e-05	0.000142	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—NRAS—skin cancer	1.92e-05	0.000142	CbGpPWpGaD
Dipyridamole—ABCC5—Metabolism—PTGS2—skin cancer	1.91e-05	0.000141	CbGpPWpGaD
Dipyridamole—PDE7B—Signaling Pathways—IL6—skin cancer	1.89e-05	0.00014	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.89e-05	0.000139	CbGpPWpGaD
Dipyridamole—ABCC4—Hemostasis—HRAS—skin cancer	1.85e-05	0.000137	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—HRAS—skin cancer	1.84e-05	0.000136	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—HRAS—skin cancer	1.84e-05	0.000136	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—KRAS—skin cancer	1.81e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—BRAF—skin cancer	1.8e-05	0.000133	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—HRAS—skin cancer	1.79e-05	0.000132	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—TP53—skin cancer	1.78e-05	0.000132	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—NRAS—skin cancer	1.77e-05	0.000131	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—NRAS—skin cancer	1.77e-05	0.000131	CbGpPWpGaD
Dipyridamole—PDE11A—Signaling Pathways—IL6—skin cancer	1.76e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE7A—Signaling Pathways—IL6—skin cancer	1.76e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—TP53—skin cancer	1.76e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—NRAS—skin cancer	1.75e-05	0.00013	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling by GPCR—IL6—skin cancer	1.72e-05	0.000127	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—TP53—skin cancer	1.71e-05	0.000126	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—HRAS—skin cancer	1.7e-05	0.000126	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—HRAS—skin cancer	1.68e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—HRAS—skin cancer	1.68e-05	0.000124	CbGpPWpGaD
Dipyridamole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.68e-05	0.000124	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—KRAS—skin cancer	1.65e-05	0.000122	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—KRAS—skin cancer	1.65e-05	0.000122	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—HRAS—skin cancer	1.64e-05	0.000121	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—HRAS—skin cancer	1.63e-05	0.000121	CbGpPWpGaD
Dipyridamole—PDE1C—Signaling Pathways—IL6—skin cancer	1.63e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—NRAS—skin cancer	1.62e-05	0.00012	CbGpPWpGaD
Dipyridamole—PDE6G—Signaling Pathways—IL6—skin cancer	1.61e-05	0.000119	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling by GPCR—IL6—skin cancer	1.61e-05	0.000119	CbGpPWpGaD
Dipyridamole—PDE10A—Signaling Pathways—IL6—skin cancer	1.57e-05	0.000116	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling by GPCR—IL6—skin cancer	1.56e-05	0.000115	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—HRAS—skin cancer	1.54e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—KRAS—skin cancer	1.52e-05	0.000113	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—KRAS—skin cancer	1.52e-05	0.000113	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—KRAS—skin cancer	1.51e-05	0.000112	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ENO2—skin cancer	1.5e-05	0.000111	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling by GPCR—IL6—skin cancer	1.47e-05	0.000109	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—NRAS—skin cancer	1.45e-05	0.000107	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—HRAS—skin cancer	1.4e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—HRAS—skin cancer	1.4e-05	0.000104	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—KRAS—skin cancer	1.39e-05	0.000103	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—NRAS—skin cancer	1.36e-05	0.0001	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling by GPCR—IL6—skin cancer	1.34e-05	9.93e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Immune System—IL6—skin cancer	1.34e-05	9.92e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—NRAS—skin cancer	1.32e-05	9.74e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—HRAS—skin cancer	1.3e-05	9.57e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—HRAS—skin cancer	1.3e-05	9.57e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—HRAS—skin cancer	1.28e-05	9.48e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—KRAS—skin cancer	1.25e-05	9.21e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—NRAS—skin cancer	1.24e-05	9.16e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Disease—IL6—skin cancer	1.24e-05	9.16e-05	CbGpPWpGaD
Dipyridamole—ABCC5—Disease—IL6—skin cancer	1.24e-05	9.16e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Immune System—IL6—skin cancer	1.23e-05	9.07e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—HRAS—skin cancer	1.18e-05	8.75e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—KRAS—skin cancer	1.17e-05	8.62e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—KRAS—skin cancer	1.14e-05	8.39e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—NRAS—skin cancer	1.13e-05	8.38e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Disease—IL6—skin cancer	1.13e-05	8.38e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—TP53—skin cancer	1.11e-05	8.18e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—KRAS—skin cancer	1.07e-05	7.89e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—HRAS—skin cancer	1.06e-05	7.83e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—TP53—skin cancer	1.04e-05	7.66e-05	CbGpPWpGaD
Dipyridamole—PDE3B—Signaling Pathways—IL6—skin cancer	1.01e-05	7.49e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—TP53—skin cancer	1.01e-05	7.45e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—HRAS—skin cancer	9.92e-06	7.33e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—KRAS—skin cancer	9.76e-06	7.21e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—HRAS—skin cancer	9.65e-06	7.13e-05	CbGpPWpGaD
Dipyridamole—PDE4A—Signaling Pathways—IL6—skin cancer	9.49e-06	7.01e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—TP53—skin cancer	9.48e-06	7.01e-05	CbGpPWpGaD
Dipyridamole—PDE3A—Signaling Pathways—IL6—skin cancer	9.23e-06	6.82e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—HRAS—skin cancer	9.07e-06	6.7e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—ERCC2—skin cancer	8.73e-06	6.45e-05	CbGpPWpGaD
Dipyridamole—PDE1A—Signaling Pathways—IL6—skin cancer	8.68e-06	6.41e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—TP53—skin cancer	8.67e-06	6.41e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—HRAS—skin cancer	8.3e-06	6.13e-05	CbGpPWpGaD
Dipyridamole—PDE1B—Signaling Pathways—IL6—skin cancer	7.94e-06	5.87e-05	CbGpPWpGaD
Dipyridamole—ABCB1—Metabolism—PTGS2—skin cancer	5.24e-06	3.87e-05	CbGpPWpGaD
